The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•30 April 2026•

1 min read

Cue Biopharma Appoints Industry Veteran Shao-Lee Lin as New CEO and President

Key Facts

1Cue Biopharma appointed Shao-Lee Lin, M.D., Ph.D., as CEO, President, and Director, succeeding Lucinda Warren.

2Lin has over 25 years of biopharmaceutical leadership experience, with previous roles at Horizon Therapeutics, AbbVie, and Gilead Sciences.

3The company recently announced a 1-for-30 reverse stock split and a milestone payment from Boehringer Ingelheim.

Cue Biopharma has announced the appointment of Shao-Lee Lin, M.D., Ph.D., as its new CEO, President, and Director, succeeding Lucinda Warren. Lin brings over 25 years of extensive biopharmaceutical leadership experience to the role, having previously held senior positions at industry giants including AbbVie, Gilead Sciences, and Horizon Therapeutics. This leadership transition occurs at a critical juncture as the company advances its CUE-401 program for autoimmune diseases. The appointment follows a recent 1-for-30 reverse stock split aimed at restructuring the company's equity position. Additionally, Cue Biopharma recently secured a milestone payment from Boehringer Ingelheim, providing a boost to its strategic initiatives. These moves are designed to stabilize the company's market position and drive its clinical pipeline forward under new veteran leadership.